These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36300887)

  • 21. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
    Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
    Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL.
    Liu H; Yang C; Zhao X; Le J; Wu G; Wei J; Liang Y; Qian W
    Onco Targets Ther; 2020; 13():10797-10806. PubMed ID: 33122918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.
    Tabari E; Lovejoy AF; Lin H; Bolen CR; Lor Saelee S; Lefkowitz JP; Kurtz DM; Bottos A; Nielsen TG; Parreira JM; Luong KT
    Leuk Lymphoma; 2024 May; 65(5):618-628. PubMed ID: 38337191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
    Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
    Front Immunol; 2023; 14():1188818. PubMed ID: 37342332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
    Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
    BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
    Trabucco SE; Sokol ES; Maund SL; Moore JA; Frampton GM; Albacker LA; Oestergaard MZ; Venstrom J; Sehn LH; Bolen CR
    Future Oncol; 2021 Nov; 17(31):4171-4183. PubMed ID: 34313135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
    Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
    Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of
    Qin Y; Chen H; Liu P; Zhang C; Yang J; Gui L; He X; Zhou L; Zhou S; Jiang S; Jiang H; Shi Y
    Cancer Biol Med; 2021 Nov; 19(6):893-909. PubMed ID: 34806851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.
    Zhou L; Zhao H; Shao Y; Chen X; Hong R; Wang L; Ni F; Nagler A; Hu Y; Huang H
    J Cancer; 2021; 12(18):5423-5431. PubMed ID: 34405005
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
    Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
    BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumor DNA assisting lymphoma genetic feature profiling and identification.
    Wang H; Wang Z; Zhu S; Li Z; Yang H; Sun P; Zhu M; Zhao X; Shen L; Ou Q; Yang H; Li ZM
    Ann Hematol; 2024 Oct; 103(10):4135-4144. PubMed ID: 39012515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA.
    Chen C; Di Y; Zhuang Z; Cai H; Jia C; Wang W; Zhao D; Wei C; Zhang W; Zhou D; Zhang Y
    J Cell Mol Med; 2024 Jul; 28(14):e18576. PubMed ID: 39054569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma.
    Wei C; Wang W; Zhang Y; Zhao D; Zhang W; Zhou D
    Br J Haematol; 2023 Jul; 202(1):86-95. PubMed ID: 37132364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted sequencing reveals the relationship between mutations and patients' clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma.
    Ma G; Gao Y; Jing X; He C; Liu H; Wu X; Gao Z; Li Y; Zhang S; Zhao G
    Leuk Lymphoma; 2023 Jan; 64(1):140-150. PubMed ID: 36215154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.
    Camus V; Sarafan-Vasseur N; Bohers E; Dubois S; Mareschal S; Bertrand P; Viailly PJ; Ruminy P; Maingonnat C; Lemasle E; Stamatoullas A; Picquenot JM; Cornic M; Beaussire L; Bastard C; Frebourg T; Tilly H; Jardin F
    Leuk Lymphoma; 2016 Sep; 57(9):2171-9. PubMed ID: 26883583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.
    Zhu Y; Fu D; Shi Q; Shi Z; Dong L; Yi H; Liu Z; Feng Y; Liu Q; Fang H; Cheng S; Wang L; Tian Q; Xu P; Zhao W
    Front Immunol; 2022; 13():842439. PubMed ID: 35401516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.
    Lee MJ; Koff JL; Switchenko JM; Jhaney CI; Harkins RA; Patel SP; Dave SS; Flowers CR
    Cancer; 2020 Aug; 126(15):3493-3503. PubMed ID: 32469082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
    Michot JM; Quivoron C; Sarkozy C; Danu A; Lazarovici J; Saleh K; El-Dakdouki Y; Goldschmidt V; Bigenwald C; Dragani M; Bahleda R; Baldini C; Arfi-Rouche J; Martin-Romano P; Tselikas L; Gazzah A; Hollebecque A; Lacroix L; Ghez D; Vergé V; Marzac C; Cotteret S; Rahali W; Soria JC; Massard C; Bernard OA; Dartigues P; Camara-Clayette V; Ribrag V
    Am J Hematol; 2023 Apr; 98(4):645-657. PubMed ID: 36606708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.
    Herrera AF; Tracy S; Croft B; Opat S; Ray J; Lovejoy AF; Musick L; Paulson JN; Sehn LH; Jiang Y
    Blood Adv; 2022 Mar; 6(6):1651-1660. PubMed ID: 35086141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.